Hypertension and Obesity (E Reisin, Section Editor)

Current Hypertension Reports

, 16:455

First online:

Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents

  • Pelbreton C. BalfourJr.Affiliated withDivision of Public Health Sciences, Wake Forest School of Medicine
  • , Carlos J. RodriguezAffiliated withDivision of Public Health Sciences, Wake Forest School of Medicine
  • , Keith C. FerdinandAffiliated withHeart and Vascular Institute, Tulane University School of MedicineTulane School of Medicine, Tulane Heart and Vascular Institute Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Despite remarkable declines in US cardiovascular disease morbidity and mortality over the last several decades, the prevalence of risk factors such as type 2 diabetes and hypertension remains high, associated with increasing obesity rates. Although optimal glycemic control remains a primary focus to decrease the disease burden, the FDA has issued guidance recommendations for documenting cardiovascular disease-related safety with research trials on new antidiabetic agents with more demanding requirements compared to past approval of existing therapies. This review will discuss the public health impact of type 2 diabetes, specifically with comorbid hypertension; mechanisms of action of the newest antidiabetic drug classes; and preliminary findings and potential clinical significance of the favorable blood pressure and body weight effects of the sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists; and additionally discuss two recent large cardiovascular outcome trials with dipeptidyl peptidase-4 inhibitors.


Diabetes Hypertension Antidiabetic drugs Cardiovascular disease Sodium-glucose cotransporter 2 inhibitors Glucagon-like peptide-1 receptor agonists Dipeptidyl peptidase-4 inhibitors Systolic blood pressure Obesity